GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Voyager Therapeutics
Voyager Therapeutics is a biotech company specializing in gene therapy for neurological diseases. Its stock price reflects both the field's significant potential and past failures and concerns about the safety and efficacy of its approach.
Share prices of companies in the market segment - Neuro
Voyager Therapeutics is developing gene therapy for severe neurological diseases such as Parkinson's disease and amyotrophic lateral sclerosis. We've categorized it under "Neurology." The chart below reflects how investors assess the risks and prospects in this complex area of medicine.
Broad Market Index - GURU.Markets
Voyager Therapeutics is developing gene therapy for severe neurological diseases such as Parkinson's disease and amyotrophic lateral sclerosis. We've categorized it under "Neurology." The chart below reflects how investors assess the risks and prospects in this complex area of medicine.
Change in the price of a company, segment, and market as a whole per day
VYGR - Daily change in the company's share price Voyager Therapeutics
Voyager, a gene therapy company, experiences daily fluctuations that reflect the inherent volatility of biotech. change_co measures reactions to research data and partnership news. This metric is essential for analyzing high-risk pharmaceutical companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Voyager Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with VYGR, which focuses on CNS gene therapy, helps us assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Voyager is a biopharmaceutical company specializing in gene therapy for neurological diseases. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Voyager's technology.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Voyager Therapeutics
Voyager Therapeutics' year-over-year performance is the story of its gene therapy capsid platform. Its market capitalization over the past 12 months has grown not so much from its own developments as from major licensing deals with pharmaceutical giants like Novartis, which are willing to pay hundreds of millions for access to its cutting-edge gene delivery technologies.
Annual dynamics of market capitalization of the market segment - Neuro
Voyager Therapeutics, Inc. is a biotech company specializing in the development of gene therapies for the treatment of neurological diseases. Its stock price reflects both the potential of its scientific platform and the risks associated with clinical trials and partnerships, which are typical for the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Voyager Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new gene therapy trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Voyager Therapeutics
Voyager, a gene therapy company, has a speculative price trend. Monthly fluctuations on the chart reflect not revenue, but rather news about clinical trials of its drugs for neurological diseases and partnerships with major pharmaceutical companies using its gene delivery technology.
Monthly dynamics of market capitalization of the market segment - Neuro
Voyager Therapeutics is developing gene therapy for severe neurological diseases using advanced gene delivery technologies. The chart below reflects investor sentiment in the neuroscience sector, where the need for effective treatments is particularly acute.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Voyager Therapeutics is a biotech company focused on gene therapy for central nervous system disorders. Its stock is highly volatile, driven by clinical trial results and partnerships with major pharmaceutical companies. It's a classic biotech story, unrelated to the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Voyager Therapeutics
Shares of Voyager Therapeutics, a company developing gene therapies for neurological diseases, are extremely news-sensitive. Weekly price movements reflect clinical trial data and partnerships with major pharmaceutical companies. The chart below shows how short-term developments in this complex area of medicine can cause sharp fluctuations.
Weekly dynamics of market capitalization of the market segment - Neuro
How does Voyager Therapeutics' performance compare to the pharma sector? The chart below compares the weekly stock price movements of this gene therapy company with the industry average. This helps us understand how its high volatility, driven by news about clinical trials in neuroscience, differs from that of more stable large pharma companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Voyager Therapeutics is developing gene therapy for severe neurological diseases. This chart compares its weekly volatility with the market. It shows how its shares are driven by expectations of clinical trial results, completely ignoring macroeconomic news.
Market capitalization of the company, segment and market as a whole
VYGR - Market capitalization of the company Voyager Therapeutics
The chart below shows Voyager Therapeutics' valuation, reflecting its expertise in developing adeno-associated viruses (AAVs) for gene therapy delivery. The company's market capitalization now depends less on its own drugs and more on partnerships with major pharmaceutical companies. The dynamics show how the market values it as a technology platform.
VYGR - Share of the company's market capitalization Voyager Therapeutics within the market segment - Neuro
Voyager Therapeutics is a biotech company with a significant market share in gene therapy for severe neurological diseases. Its market capitalization reflects both the potential of its developments and its innovative gene delivery capsids.
Market capitalization of the market segment - Neuro
Here's a chart of the total market capitalization of companies involved in CNS gene therapy. Voyager Therapeutics is a pioneer in this complex field. The chart shows how the market values brain gene delivery technologies that could treat previously incurable diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes hope for patients with Parkinson's and Huntington's diseases. Voyager Therapeutics' market cap reflects the potential of its brain gene delivery platform. The line shows how this breakthrough technology, targeting incurable neurological diseases, is shaping its share of the global biotechnology market.
Book value capitalization of the company, segment and market as a whole
VYGR - Book value capitalization of the company Voyager Therapeutics
Voyager Therapeutics' book value represents its scientific capital. The chart below reflects the valuation of its patents on a platform for creating capsids (viral shells) capable of delivering gene therapy to the central nervous system. The line's growth signals progress in developing a key technology for treating neurological diseases.
VYGR - Share of the company's book capitalization Voyager Therapeutics within the market segment - Neuro
Voyager Therapeutics' tangible assets include its laboratories and equipment for developing next-generation gene therapy vectors capable of crossing the blood-brain barrier. The chart shows its stake in this unique scientific infrastructure, which is key to treating brain diseases.
Market segment balance sheet capitalization - Neuro
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Voyager, which is developing gene therapy for the central nervous system, looks like a "lightweight." Its value lies in its unique gene delivery technology and patents, not in large factories. Its business is based on cutting-edge science.
Book value of all companies included in the broad market index - GURU.Markets
Voyager Therapeutics develops gene therapy for the treatment of severe neurological diseases. The company's assets are not drugs, but rather a gene delivery technology (capsids) for the brain and a development pipeline. The balance of these assets is the cost of a "transport system" that can deliver genetic "repair code" to the most difficult-to-reach cells.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Voyager Therapeutics
Voyager's balance sheet is made up of its cash and gene therapy platform. Its market capitalization is a valuation of its partnerships with large companies that use its gene delivery technology. The MvsBCap_Co chart shows that the market values it as a technology provider rather than as a standalone drug developer.
Market to book capitalization ratio in a market segment - Neuro
Voyager Therapeutics is developing gene therapy for the treatment of severe neurological diseases. Its value lies in its technology for delivering genes to the brain. The chart shows the high market valuation of its scientific platform and partnerships, reflecting hopes for breakthroughs in the treatment of Parkinson's and Huntington's diseases.
Market to book capitalization ratio for the market as a whole
Voyager Therapeutics is a biotech company developing gene therapies for severe neurological diseases such as Parkinson's disease and amyotrophic lateral sclerosis. Its value lies in its scientific platform. This chart illustrates why investors are willing to pay a premium for breakthrough approaches to treating CNS diseases.
Debts of the company, segment and market as a whole
VYGR - Company debts Voyager Therapeutics
For Voyager Therapeutics, a company developing gene therapies for neurological diseases, debt is key to advancing its platform. This chart shows how the company raises capital for preclinical and clinical trials of its drug candidates. In this industry, debt is an investment in technologies capable of treating diseases at the DNA level.
Market segment debts - Neuro
Voyager Therapeutics is a biotech company specializing in developing gene therapies for the treatment of severe neurological diseases. Delivering genes to the brain is an extremely complex task. This chart shows how the company funds its cutting-edge, yet highly risky and capital-intensive, research in this area.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Voyager Therapeutics
Voyager Therapeutics is developing gene therapy for severe neurological diseases. This chart shows how the company is funding its breakthrough but risky research. A high debt load for such a company is a bet on the future that could yield huge returns if successful or lead to serious financial problems if unsuccessful.
Market segment debt to market segment book capitalization - Neuro
Voyager Therapeutics is developing gene therapy for the treatment of severe neurological diseases. Delivering genes to the brain is one of the most complex challenges in medicine. The chart shows how the company's debt load, used to finance breakthrough but risky research, compares to the market capitalization of the entire biotech sector.
Debt to book value of all companies in the market
Voyager Therapeutics (VYGR) is a biotech company specializing in gene therapy for severe neurological diseases. Cutting-edge research requires significant capital investment. This chart shows the overall market debt load. It helps explain why Voyager, like many biotechs, avoids debt to maintain flexibility during the lengthy research process.
P/E of the company, segment and market as a whole
P/E - Voyager Therapeutics
For Voyager Therapeutics, a company developing gene therapy for neurological diseases, this chart reflects both enormous potential and significant risks. There is no P/E ratio. The company's valuation depends on the success of its brain gene delivery platform and the results of clinical trials, which are particularly complex and lengthy in this field.
P/E of the market segment - Neuro
Here's the average P/E for biotech companies working in neuroscience. For Voyager Therapeutics, it serves as a benchmark. It reflects the overall level of hope and disappointment in this complex field, providing context for assessing the risks and potential associated with its brain gene therapy platform.
P/E of the market as a whole
Voyager Therapeutics is a biotech company specializing in gene therapy for severe neurological diseases. The company uses advanced viral vectors to deliver therapeutic genes to the brain. This risk appetite chart helps understand how investors view this complex area of medicine.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Voyager Therapeutics
Voyager Therapeutics is a biotech company developing gene therapy for the treatment of severe neurological diseases. This graph reflects expectations for its scientific platform and its ability to deliver therapeutic genes to the brain. This estimate depends on the results of clinical trials and partnerships that will help fund costly research.
%20P%2FE%20Voyager%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Voyager-Therapeutics&v=1772669572146 "Chart of the company's future (projected) P/E Voyager Therapeutics")
Future (projected) P/E of the market segment - Neuro
Voyager Therapeutics is a biotech company specializing in gene therapy for the treatment of severe neurological diseases. This chart reflects the company's long-term profitability expectations. It demonstrates how highly the market values their innovative approaches to delivering genes to the brain and the potential of their therapeutic programs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772669572180 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Voyager Therapeutics is developing gene therapy for the treatment of severe neurological diseases. Its valuation is based on the potential of its scientific platform. This market expectations chart reflects investor willingness to fund long-term, high-risk biotech projects. Market optimism is key to accessing capital.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772669572198 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy for the treatment of severe neurological diseases such as Parkinson's disease and amyotrophic lateral sclerosis. Its financial performance reflects its expenditures on clinical research and the development of viral vectors for gene delivery to the brain.
Profit of companies in the market segment - Neuro
Voyager Therapeutics is developing gene therapy for the treatment of severe neurological diseases. The company's success depends on the results of clinical trials and the safety of its delivery vectors. This graph highlights the high risks and potential of CNS gene therapy, where a single successful drug could become a blockbuster and dramatically change patients' lives.
Overall market profit
Voyager Therapeutics is a biotech company developing gene therapy for the treatment of severe neurological diseases. Its success depends on the results of clinical trials and the safety of its viral vectors. This is a high-risk field, where value is created by science, not by macroeconomic trends.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Voyager Therapeutics
Voyager Therapeutics is developing gene therapy for the treatment of severe neurological diseases. This timeline reflects expectations, which hinge on the success of its platform and the ability to safely deliver therapeutic genes to the brain. Partnerships with major pharmaceutical companies, such as Neurocrine, are key to these projections.
%20profit%20of%20the%20company%20Voyager%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Voyager-Therapeutics&v=1772669572343 "Graph of future (projected) profit of the company Voyager Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Voyager Therapeutics is developing gene therapy for the treatment of severe neurological diseases such as Parkinson's disease and amyotrophic lateral sclerosis. This chart shows the revenue forecast for the entire neuropharmaceutical sector. It reflects the expected success of gene therapy. This background is important for assessing the potential of Voyager's advanced drug delivery vectors.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772669572396 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Voyager Therapeutics is developing gene therapy for the treatment of severe neurological diseases. Like other companies in this field, it is entirely dependent on the success of clinical trials and its ability to raise capital. The general economic forecasts presented here influence the investment climate in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772669572460 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Voyager Therapeutics
Voyager Therapeutics is a biotech company developing gene therapies for severe neurological diseases. It uses innovative viral vectors (capsids) to deliver therapeutic genes to the brain. This chart shows how investors view its cutting-edge technology platform and its partnerships with major pharmaceutical companies.
P/S market segment - Neuro
Voyager Therapeutics is a biotech company specializing in developing gene therapies for the treatment of severe neurological diseases such as Parkinson's disease and amyotrophic lateral sclerosis (ALS). This chart shows the average valuation in the sector, helping to understand the market premium placed on the potentially breakthrough treatments Voyager is developing.
P/S of the market as a whole
Voyager Therapeutics is a biotech company specializing in gene therapy for severe neurological diseases. The company is developing new viral vectors for more precise and safe gene delivery to the brain. This market valuation chart helps understand the premium investors are paying for this potentially breakthrough, yet highly risky, venture.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Voyager Therapeutics
Voyager Therapeutics is developing gene therapy for the treatment of severe neurological diseases. Without commercial products, its value is determined by future prospects. This chart reflects market expectations regarding the success of its clinical programs and the potential of gene therapy in neurology.
%20P%2FS%20Voyager%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Voyager-Therapeutics&v=1772669572641 "The graph of the company's future (projected) P/S Voyager Therapeutics")
Future (projected) P/S of the market segment - Neuro
Voyager Therapeutics is a biotech company specializing in gene therapy for severe neurological diseases. This chart compares market expectations for its future revenue with other neuroscience companies. The valuation reflects investor confidence in its brain gene delivery platform and its partnerships with major pharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772669572716 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Voyager Therapeutics specializes in gene therapy for severe neurological diseases. Its valuation is a bet on a future scientific breakthrough. The overall market optimism reflected in this chart is critical, as it provides access to the capital needed to conduct lengthy and expensive clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772669572781 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Voyager Therapeutics
Voyager Therapeutics is a biotechnology company developing gene therapies for the treatment of severe neurological diseases such as Parkinson's disease and amyotrophic lateral sclerosis. Its revenue comes from strategic partnerships with major pharmaceutical companies. The chart reflects funding supporting its cutting-edge clinical programs.
Sales of companies in the market segment - Neuro
Voyager Therapeutics is a biotechnology company specializing in the development of gene therapies for the treatment of severe neurological diseases. The company uses adeno-associated viruses (AAVs) to deliver therapeutic genes to the brain. Revenue is generated from partnerships. This chart illustrates the potential of gene therapy in neurology, where Voyager is a technology leader.
Overall market sales
Voyager Therapeutics is a biotech company developing the complex field of gene therapy for neurological diseases. Its success depends on scientific breakthroughs, not current sales. However, this chart, reflecting the overall investment climate, is critically important, as it is during periods of economic growth that investors are most willing to fund the long-term, risky projects that shape Voyager's future.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Voyager Therapeutics
Voyager Therapeutics is developing gene therapy for the treatment of severe neurological diseases such as Parkinson's disease and amyotrophic lateral sclerosis (ALS). This timeline reflects analyst expectations for the success of its clinical programs and its technology platform aimed at delivering genes to the brain.
%20sales%20of%20the%20company%20Voyager%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Voyager-Therapeutics&v=1772669572985 "Schedule of future (projected) sales of the company Voyager Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Voyager Therapeutics is developing gene therapy for severe neurological diseases using advanced gene delivery technologies. This chart shows the overall outlook for the neuroscience sector. Investors should evaluate how partnerships with major companies and progress in clinical trials impact the prospects of this high-risk technology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772669573015 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Voyager Therapeutics is developing gene therapy for the treatment of severe neurological diseases. This graph, reflecting the investment climate in biotech, is important for the company. Developing such complex treatments requires significant and long-term investment, and the availability of capital, linked to the overall economic situation, is a key factor for Voyager.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772669573101 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Voyager Therapeutics
Voyager Therapeutics is at the forefront of gene therapy, developing treatments for severe neurological diseases. Its business is not driven by current sales, but by long-term investments in breakthrough science, requiring massive expenditures on clinical trials. This chart clearly demonstrates the "cost of innovation"—the financial investment required to create drugs that could one day change the lives of millions.
Market segment marginality - Neuro
Voyager Therapeutics is developing gene therapy for severe neurological diseases such as Parkinson's disease and amyotrophic lateral sclerosis. Their goal is to precisely deliver the therapeutic gene to the brain. This chart shows the scale of their investment in their cutting-edge delivery platform, which is key to success in this complex area of medicine.
Market marginality as a whole
Voyager Therapeutics is a biotech company specializing in gene therapy for severe neurological diseases. The overall profitability picture is irrelevant for them. Their value lies in their unique technologies for delivering genes to the brain. Success depends on clinical trial results and partnerships with major pharmaceutical companies.
Employees in the company, segment and market as a whole
Number of employees in the company Voyager Therapeutics
Voyager Therapeutics is a biotech company specializing in gene therapy for neurological diseases. This graph shows the team of scientists working on creating more advanced viral vectors. The staff dynamics reflect both progress in their own programs and partnerships with other companies.
Share of the company's employees Voyager Therapeutics within the market segment - Neuro
Voyager Therapeutics is a biotech company specializing in developing gene therapies for the treatment of severe neurological diseases. This chart shows the percentage of leading neurogenetic scientists the company attracts. This reflects its focus on CNS diseases and its team working to develop breakthrough treatments.
Number of employees in the market segment - Neuro
Voyager Therapeutics is a biotech company specializing in the development of gene therapies for the treatment of severe neurological diseases. This chart shows employment in the biotech sector. The dynamics of headcount, particularly among researchers, reflect the successes and challenges of clinical trials, which are key for companies in this cutting-edge field.
Number of employees in the market as a whole
Voyager Therapeutics develops gene therapies to treat severe neurological diseases such as Parkinson's disease and amyotrophic lateral sclerosis (ALS). This is one of the most complex areas of medicine. This graph shows overall employment, and companies like Voyager are growth areas requiring the best minds in neurology, genetics, and virology.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Voyager Therapeutics (VYGR)
Voyager Therapeutics, Inc. is a biotech company developing gene therapies for the treatment of severe neurological diseases. Its valuation is determined by the potential of its scientific research. This chart illustrates a model with a very high market capitalization per employee. Investors are betting that a small team of scientists will be able to create a breakthrough drug.
%20of%20the%20company%20Voyager%20Therapeutics%20(VYGR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Voyager-Therapeutics-VYGR&v=1772669573492 "Chart of market capitalization per employee (in thousands of dollars) of the company Voyager Therapeutics (VYGR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Nuveen Real Estate Income Fund is a closed-end mutual fund investing in real estate debt obligations. Like other funds, it has virtually no employees. This ratio, which is very high here, reflects not operational efficiency but the structure of the financial product, where the value of the assets is attributed to the management team.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772669573574 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Voyager Therapeutics specializes in developing gene therapies for the treatment of severe neurological diseases. The company's value lies in its viral vectors (gene carriers) and partnerships. This chart demonstrates the high market value per employee, demonstrating the value of their unique technology platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772669573638 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Voyager Therapeutics (VYGR)
Voyager Therapeutics is a biotech company working at the forefront of science, developing gene therapies for the treatment of severe neurological diseases such as Parkinson's disease. This metric reflects the "cost" of this breakthrough research: it measures the negative profit (expense) per highly qualified scientist working on gene therapy development.
%20Chart%20Voyager%20Therapeutics%20(VYGR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Voyager-Therapeutics-VYGR&v=1772669573662 "Company Profit Per Employee (in thousands of dollars) Chart Voyager Therapeutics (VYGR)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Voyager Therapeutics is a biotech company specializing in gene therapy for neurological diseases. Their specialty is developing new vectors for delivering genes to the brain. This chart demonstrates the benchmark for biotech staff efficiency. It's important for assessing how effectively Voyager is monetizing its unique R&D platform.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772669573681 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Voyager Therapeutics is a biotech company focused on gene therapy for severe neurological diseases (such as Parkinson's disease). Delivering genes to the brain is a formidable challenge. The chart shows the R&D investment (negative return) per scientist working on this cutting-edge technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772669573684 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Voyager Therapeutics (VYGR)
Voyager Therapeutics is a biotech company developing gene therapies for the treatment of severe neurological diseases. This chart shows its status as an R&D company. Revenue comes primarily from partnerships with major pharmaceutical companies, rather than from sales, as its own products are still in development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Voyager-Therapeutics-VYGR&v=1772669573699 "Sales chart per company employee Voyager Therapeutics (VYGR)")
Sales per employee in the market segment - Neuro
Voyager Therapeutics (VYGR) is a biotech company specializing in gene therapy for central nervous system diseases (e.g., Parkinson's, ALS). They are known for their vector (capsid) platform. This graph shows how much revenue (from partnerships) each employee (scientist) generates. This is an indicator of the value of their R&D platform and gene delivery technologies.
Sales per employee for the market as a whole
Voyager Therapeutics is a biotech company focused on gene therapy for neurological diseases. It is an R&D platform. This chart illustrates their business model: revenue is generated not through drug sales, but through large upfront payments from partners (such as Neurocrine) who license their technologies. This demonstrates the high value of their IP.
Short shares by company, segment and market as a whole
Shares shorted by company Voyager Therapeutics (VYGR)
Voyager Therapeutics is a biotech company specializing in gene therapy for severe neurological diseases. This chart shows bearish bets. The shorts are driven by enormous risks: brain gene therapy is extremely complex, and the company has previously encountered serious side effects in trials, leading to their termination.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Voyager-Therapeutics-VYGR&v=1772669573757 "Short Shares Chart for the Company Voyager Therapeutics (VYGR)")
Shares shorted by market segment - Neuro
Voyager Therapeutics (VYGR) is a biotech company specializing in gene therapy for severe neurological diseases (Parkinson's, ALS). This chart shows the bets against the gene therapy sector. The rising bets against the industry reflect investor skepticism about the safety (delivery of viruses to the brain) and efficacy of these complex treatments.
Shares shorted by the overall market
Voyager Therapeutics is a clinical-stage company betting on gene therapy to treat severe neurological diseases. This chart shows the overall level of pessimism in the market. When it rises, investors avert risk en masse. Speculative, cash-burning biotechs like VYGR are the first to be sold off, as their path to profitability is long, and access to funding becomes difficult in such a fearful environment.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Voyager Therapeutics (VYGR)
Voyager Therapeutics is a biotech company focused on gene therapy for the central nervous system. Its stock is extremely volatile. This chart can surge above 70 on positive trial data or partnerships. Oversold levels (<30) are often associated with research setbacks or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Voyager-Therapeutics-VYGR&v=1772669573863 "RSI 14 indicator chart for the company's stock Voyager Therapeutics (VYGR)")
RSI 14 Market Segment - Neuro
Voyager Therapeutics is a biotech company specializing in gene therapy for severe neurological diseases such as Parkinson's. This sector is highly dependent on clinical trial data. This chart shows the overall momentum in the neuro biotech segment. It helps distinguish the reaction to VYGR's news from general euphoria or industry-wide panic.
RSI 14 for the overall market
Voyager Therapeutics (VYGR) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VYGR (Voyager Therapeutics)
Voyager Therapeutics is a biotech company developing gene therapies for severe neurological diseases (Parkinson's, ALS) using its advanced "vectors" (capsids) for delivery. This chart shows the average analyst forecast. Their targets are based on the success of clinical trials and the value of their capsid platform for partners.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VYGR-Voyager-Therapeutics&v=1772669573905 "A chart showing analyst consensus forecasts for the expected stock price. VYGR (Voyager Therapeutics)")
The difference between the consensus estimate and the actual stock price VYGR (Voyager Therapeutics)
Voyager Therapeutics (VYGR) is a biotech company specializing in the development of gene therapy vectors (carriers) that can safely deliver drugs to the brain (CNS). This chart shows the valuation of their technology. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their delivery platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VYGR-Voyager-Therapeutics&v=1772669573920 "A chart showing the difference between the consensus forecast and the actual stock price. VYGR (Voyager Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Voyager Therapeutics (VYGR) is a biotech company specializing in gene therapy for the central nervous system. Its key asset is capsids (viral shells) capable of delivering genes to the brain. This chart shows the general expectations of analysts in the neuroscience sector. It reflects whether experts believe in the future of brain gene therapy.
Analysts' consensus forecast for the overall market share price
Voyager Therapeutics is a biotech company specializing in gene therapy for severe neurological diseases. They are known for their "vectors" (capsids) for delivering drugs to the brain. This chart shows the overall "risk appetite." For Voyager, which operates in the complex field of neuroscience, overall market optimism (a rising chart) is critical for funding long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Voyager Therapeutics
Voyager Therapeutics is a biotech company that pioneered gene therapy for the central nervous system (brain). After some setbacks, they rebooted and are now focusing on creating next-generation capsids (viral shells) for gene delivery. This graph summarizes their progress, reflecting their ability to license these new shells to major pharma partners.
AKIMA Market Segment Index - Neuro
Voyager Therapeutics specializes in gene therapy for severe neurological diseases, using viral vectors (AAVs) to deliver drugs to the brain. This chart shows the average index for the neurosegment. It provides investors with a benchmark for how Voyager's performance, which focuses on the most complex diseases, compares to the sector average.
The AKIM Index for the overall market
Voyager Therapeutics is an expert in AAV capsids for gene therapy. The company develops vectors capable of penetrating the brain (neurology). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this platform company, which is making deals with pharma, compares to overall economic trends.
